[go: up one dir, main page]

GB0025058D0 - Composition - Google Patents

Composition

Info

Publication number
GB0025058D0
GB0025058D0 GBGB0025058.9A GB0025058A GB0025058D0 GB 0025058 D0 GB0025058 D0 GB 0025058D0 GB 0025058 A GB0025058 A GB 0025058A GB 0025058 D0 GB0025058 D0 GB 0025058D0
Authority
GB
United Kingdom
Prior art keywords
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0025058.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Priority to GBGB0025058.9A priority Critical patent/GB0025058D0/en
Publication of GB0025058D0 publication Critical patent/GB0025058D0/en
Priority to AU2001262163A priority patent/AU2001262163A1/en
Priority to PCT/EP2001/003786 priority patent/WO2002030458A1/en
Priority to ARP010101488A priority patent/AR027738A1/en
Priority to CO01025486A priority patent/CO5270014A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB0025058.9A 2000-10-12 2000-10-12 Composition Ceased GB0025058D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GBGB0025058.9A GB0025058D0 (en) 2000-10-12 2000-10-12 Composition
AU2001262163A AU2001262163A1 (en) 2000-10-12 2001-03-26 Composition
PCT/EP2001/003786 WO2002030458A1 (en) 2000-10-12 2001-03-26 Yersinia adhesion protein as vaccine adjuvant
ARP010101488A AR027738A1 (en) 2000-10-12 2001-03-28 COMPOSITION COADYUVANTE, COMPOSITIONS OF VACCINES THAT INCLUDE SUCH COMPOSITION COADYUVANTE; PROCEDURE FOR INDUCTION OF IMMUNE IMMUNORESPUESTAS AMMAMIFEROS AND PROCEDURE OF TREATMENT WHERE SUCH VACCINES APPLY
CO01025486A CO5270014A1 (en) 2000-10-12 2001-03-30 COMPOSITION

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0025058.9A GB0025058D0 (en) 2000-10-12 2000-10-12 Composition

Publications (1)

Publication Number Publication Date
GB0025058D0 true GB0025058D0 (en) 2000-11-29

Family

ID=9901176

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0025058.9A Ceased GB0025058D0 (en) 2000-10-12 2000-10-12 Composition

Country Status (5)

Country Link
AR (1) AR027738A1 (en)
AU (1) AU2001262163A1 (en)
CO (1) CO5270014A1 (en)
GB (1) GB0025058D0 (en)
WO (1) WO2002030458A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2854803B1 (en) * 2003-05-16 2005-06-24 Aventis Pasteur VACCINE COMPOSITION COMPRISING IRON PHOSPHATE AS VACCINE.
US20080226729A1 (en) * 2006-09-08 2008-09-18 Becton, Dickinson And Company Stable powder formulations of alum-adsorbed vaccines
EP2034022A1 (en) 2007-09-10 2009-03-11 Universite Libre De Bruxelles Leukotriene B4 binding soluble lipocalin receptor from ixodes ricinus
EP2045263A1 (en) 2007-10-02 2009-04-08 Universite Libre De Bruxelles Identification and molecular characterisation of salivary metalloproteases expressed in the tick salivary glands

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5239066A (en) * 1985-07-31 1993-08-24 The Board Of Trustees Of Leland Stanford Jr. University Yersinia ail nucleic acids
US5338842A (en) * 1985-07-31 1994-08-16 The Board Of Trustees Of Leland Stanford Jr. University Yersinia INV nucleic acids
WO2000018355A2 (en) * 1998-09-30 2000-04-06 Walter Reed Army Institute Of Research Use of purified invaplex from gram negative bacteria as a vaccine
EP1131338B1 (en) * 1998-10-21 2005-03-02 The University Of Kansas Center For Research, Inc. Method for the production of purified invasin protein and use thereof

Also Published As

Publication number Publication date
CO5270014A1 (en) 2003-04-30
WO2002030458A8 (en) 2002-07-18
AR027738A1 (en) 2003-04-09
AU2001262163A1 (en) 2002-04-22
WO2002030458A1 (en) 2002-04-18

Similar Documents

Publication Publication Date Title
GB0026018D0 (en) New composition
HUP0400589A3 (en) Colostrum-based composition
SG99895A1 (en) Proanthocyanidin-containing composition
EP1320385A4 (en) Combination compositions
IL145793A0 (en) Odor-eliminating composition
GB0023891D0 (en) Composition
EP1270611A4 (en) Composition
GB0019651D0 (en) Compositions
GB0109427D0 (en) Arthropod-controlling composition
GB0003232D0 (en) Novel composition
IL150471A0 (en) Composition
GB0022473D0 (en) Composition
GB0004518D0 (en) Compositions
GB0007762D0 (en) Composition
GB0025058D0 (en) Composition
GB0031267D0 (en) Novel compositions
GB0004522D0 (en) Compositions
GB0119165D0 (en) Composition
GB0014187D0 (en) Composition
GB0001939D0 (en) Composition
GB0002320D0 (en) Composition
GB0014971D0 (en) Composition
GB0002115D0 (en) Composition
GB0029339D0 (en) Composition
GB0023418D0 (en) Composition

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)